S-Space

Browse

Author

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 21 of 21

Issue Date	Title / Author(s) / Citation	File
2010-10	Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer Kwak, Eunice L.; Bang, Yung-Jue; Camidge, D. Ross; Shaw, Alice T.; Solomon, Benjamin; Maki, Robert G.; Ou, Sai-Hong I.; Dezube, Bruce J.; Jaenne, Pasi A.; Costa, Daniel B.; Varella-Garcia, Marileila; Kim, Woo-Ho; Lynch, Thomas J.; Fidias, Panos; Stubbs, Hannah; Engelman, Jeffrey A.; Sequist, Lecia V.; Tan, WeiWei; Gandhi, Leena; Mino-Kenudson, Mari; Wei, Greg C.; Shreeve, S. Martin; Ratain, Mark J.; Settleman, Jeffrey; Christensen, James G.; Haber, Daniel A.; Wilner, Keith; Salgia, Ravi; Shapiro, Geoffrey I.; Clark, Jeffrey W.; Iafrate, A. John New England Journal of Medicine, Vol.363 No.18, pp.1693-1703	DOI
2010-12	Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer Ou, Sai-Hong Ignatius; Bazhenova, Lyudmila; Camidge, D. Ross; Solomon, Benjamin J.; Herman, June; Kain, Tatiana; Bang, Yung-Jue; Kwak, Eunice L.; Shaw, Alice T.; Salgia, Ravi; Maki, Robert G.; Clark, Jeffrey W.; Wilner, Keith D.; Iafrate, A. John Journal of Thoracic Oncology, Vol.5 No.12, pp.2044-2046	DOI
2011-05	Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification Ou, Sai-Hong Ignatius; Kwak, Eunice L.; Siwak-Tapp, Christina; Dy, Joni; Bergethon, Kristin; Clark, Jeffrey W.; Camidge, D. Ross; Solomon, Benjamin J.; Maki, Robert G.; Bang, Yung-Jue; Kim, Dong-Wan; Christensen, James; Tan, Weiwei; Wilner, Keith D.; Salgia, Ravi; Iafrate, A. John Journal of Thoracic Oncology, Vol.6 No.5, pp.942-946	DOI
2011-10	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Shaw, Alice T.; Yeap, Beow Y.; Solomon, Benjamin J.; Riely, Gregory J.; Gainor, Justin; Engelman, Jeffrey A.; Shapiro, Geoffrey I.; Costa, Daniel B.; Ou, Sai-Hong I.; Butaney, Mohit; Salgia, Ravi; Maki, Robert G.; Varella-Garcia, Marileila; Doebele, Robert C.; Bang, Yung-Jue; Kulig, Kimary; Selaru, Paulina; Tang, Yiyun; Wilner, Keith D.; Kwak, Eunice L.; Clark, Jeffrey W.; Iafrate, A. John; Camidge, D. Ross The Lancet Oncology, Vol.12 No.11, pp.1004-1012	DOI
2012-10	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Camidge, D. Ross; Bang, Yung-Jue; Kwak, Eunice L.; Iafrate, A. John; Varella-Garcia, Marileila; Fox, Stephen B.; Riely, Gregory J.; Solomon, Benjamin; Ou, Sai-Hong I.; Kim, Dong-Wan; Salgia, Ravi; Fidias, Panagiotis; Engelman, Jeffrey A.; Gandhi, Leena; Jaenne, Pasi A.; Costa, Daniel B.; Shapiro, Geoffrey I.; LoRusso, Patricia; Ruffner, Katherine; Stephenson, Patricia; Tang, Yiyun; Wilner, Keith; Clark, Jeffrey W.; Shaw, Alice T. The Lancet Oncology, Vol.13 No.10, pp.1011-1019	DOI
2013-06	Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer Shaw, Alice T.; Kim, Dong-Wan; Nakagawa, Kazuhiko; Seto, Takashi; Crino, Lucio; Ahn, Myung-Ju; De Pas, Tommaso; Besse, Benjamin; Solomon, Benjamin J.; Blackhall, Fiona; Wu, Yi-Long; Thomas, Michael; O'Byrne, Kenneth J.; Moro-Sibilot, Denis; Camidge, D. Ross; Mok, Tony; Hirsh, Vera; Riely, Gregory J.; Iyer, Shrividya; Tassell, Vanessa; Polli, Anna; Wilner, Keith D.; Jaenne, Pasi A. New England Journal of Medicine, Vol.368 No.25, pp.2385-2394	DOI
2014-03	Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer Shaw, Alice T.; Kim, Dong-Wan; Mehra, Ranee; Tan, Daniel S. W.; Felip, Enriqueta; Chow, Laura Q. M.; Camidge, D. Ross; Vansteenkiste, Johan; Sharma, Sunil; De Pas, Tommaso; Riely, Gregory J.; Solomon, Benjamin J.; Wolf, Juergen; Thomas, Michael; Schuler, Martin; Liu, Geoffrey; Santoro, Armando; Lau, Yvonne Y.; Goldwasser, Meredith; Boral, Anthony L.; Engelman, Jeffrey A. New England Journal of Medicine, Vol.370 No.13, pp.1189-1197	DOI
2014-11	Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer Shaw, Alice T.; Ou, Sai-Hong I.; Bang, Yung-Jue; Camidge, D. Ross; Solomon, Benjamin J.; Salgia, Ravi; Riely, Gregory J.; Varella-Garcia, Marileila; Shapiro, Geoffrey I.; Costa, Daniel B.; Doebele, Robert C.; Long Phi Le; Zheng, Zongli; Tan, Weiwei; Stephenson, Patricia; Shreeve, S. Martin; Tye, Lesley M.; Christensen, James G.; Wilner, Keith D.; Clark, Jeffrey W.; Iafrate, A. John New England Journal of Medicine, Vol.371 No.21, pp.1963-1971	DOI
2016-04	Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial Kim, Dong-Wan; Mehra, Ranee; Tan, Daniel S. W.; Felip, Enriqueta; Chow, Laura Q. M.; Camidge, D. Ross; Vansteenkiste, Johan; Sharma, Sunil; De Pas, Tommaso; Riely, Gregory J.; Solomon, Benjamin J.; Wolf, Juergen; Thomas, Michael; Schuler, Martin; Liu, Geoffrey; Santoro, Armando; Sutradhar, Santosh; Li, Siyu; Szczudlo, Tomasz; Yovine, Alejandro; Shaw, Alice T. The Lancet Oncology, Vol.17 No.4, pp.452-463	DOI
2016-12	Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer Gadgeel, Shirish M.; Shaw, Alice T.; Govindan, Ramaswamy; Gandhi, Leena; Socinski, Mark A.; Camidge, D. Ross; De Petris, Luigi; Kim, Dong-Wan; Chiappori, Alberto; Moro-Sibilot, Denis L.; Duruisseaux, Michael; Crino, Lucio; De Pas, Tommaso; Dansin, Eric; Tessmer, Antje; Yang, James Chih-Hsin; Han, Ji-Youn; Bordogna, Walter; Golding, Sophie; Zeaiter, Ali; Ou, Sai-Hong Ignatius Journal of Clinical Oncology, Vol.34 No.34, pp.4079-4085	DOI
2017-08	Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial Kim, Dong-Wan; Tiseo, Marcello; Ahn, Myung-Ju; Reckamp, Karen L.; Hansen, Karin Holmskov; Kim, Sang-We; Huber, Rudolf M.; West, Howard L.; Groen, Harry J. M.; Hochmair, Maximilian J.; Leighl, Natasha B.; Gettinger, Scott N.; Langer, Corey J.; Rodriguez, Luis G. Paz-Ares; Smit, Egbert F.; Kim, Edward S.; Reichmann, William; Haluska, Frank G.; Kerstein, David; Camidge, D. Ross Journal of Clinical Oncology, Vol.35 No.22, pp.2490-2498	DOI
2017-09	Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria Gandhi, Leena; Ou, Sai-Hong Ignatius; Shaw, Alice T.; Barlesi, Fabrice; Dingemans, Anne-Marie C.; Kim, Dong-Wan; Camidge, D. Ross; Hughes, Brett G. M.; Yang, James C. -H.; de Castro, Javier; Crino, Lucio; Lena, Herve; Do, Pascal; Golding, Sophie; Bordogna, Walter; Zeaiter, Ali; Kotb, Ahmed; Gadgeel, Shirish European Journal of Cancer, Vol.82, pp.27-33	DOI
2018-09	Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials Camidge, D. Ross; Kim, Dong-Wan; Tiseo, Marcello; Langer, Corey J.; Ahn, Myung-Ju; Shaw, Alice T.; Huber, Rudolf M.; Hochmair, Maximilian J.; Lee, Dae Ho; Bazhenova, Lyudmila A.; Gold, Kathryn A.; Ou, Sai-Hong Ignatius; West, Howard L.; Reichmann, William; Haney, Jeff; Clackson, Tim; Kerstein, David; Gettinger, Scott N. Journal of Clinical Oncology, Vol.36 No.26, pp.2693-2701	DOI
2020-03	Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial Huber, Rudolf M.; Hansen, Karin H.; Paz-Ares Rodriguez, Luis; West, Howard L.; Reckamp, Karen L.; Leighl, Natasha B.; Tiseo, Marcello; Smit, Egbert F.; Kim, Dong-Wan; Gettinger, Scott N.; Hochmair, Maximilian J.; Kim, Sang-We; Langer, Corey J.; Ahn, Myung-Ju; Kim, Edward S.; Kerstein, David; Groen, Harry J. M.; Camidge, D. Ross Journal of Thoracic Oncology, Vol.15 No.3, pp.404-415	DOI
2020-11	Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial Camidge, D. Ross; Kim, Hye Ryun; Ahn, Myung-Ju; Yang, James C. H.; Han, Ji-Youn; Hochmair, Maximilian J.; Lee, Ki Hyeong; Delmonte, Angelo; Garcia Campelo, Maria Rosario; Kim, Dong-Wan; Griesinger, Frank; Felip, Enriqueta; Califano, Raffaele; Spira, Alexander; Gettinger, Scott N.; Tiseo, Marcello; Lin, Huamao M.; Gupta, Neeraj; Hanley, Michael J.; Ni, Quanhong; Zhang, Pingkuan; Popat, Sanjay Journal of Clinical Oncology, Vol.38 No.31, pp.3592-3603	DOI
2021-02	Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study Mok, Tony; Peters, Solange; Camidge, D. Ross; Noe, Johannes; Gadgeel, Shirish; Ou, Sai-Hong Ignatius; Kim, Dong-Wan; Konopa, Krzysztof; Pozzi, Emanuela; Liu, Ting; Loftin, Isabell R.; Williams, Crystal; Shaw, Alice T. Journal of Thoracic Oncology, Vol.16 No.2, pp.259-268	DOI
2021-12	Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial Camidge, D. Ross; Kim, Hye Ryun; Ahn, Myung-Ju; Yang, James C. H.; Han, Ji-Youn; Hochmair, Maximilian J.; Lee, Ki Hyeong; Delmonte, Angelo; Campelo, D. h Maria Rosario Garcia; Kim, Dong-Wan; Griesinger, Frank; Felip, Enriqueta; Califano, Raffaele; Spira, Alexander I.; Gettinger, Scott N.; Tiseo, Marcello; Lin, Huamao M.; Liu, Yuyin; Vranceanu, Florin; Niu, Huifeng; Zhang, Pingkuan; Popat, Sanjay Journal of Thoracic Oncology, Vol.16 No.12, pp.2091-2108	DOI
2022-08	First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors Kim, Tae Won; Burris, Howard A.; Luken, Maria J. de Miguel; Pishvaian, Michael J.; Bang, Yung-Jue; Gordon, Michael; Awada, Ahmad; Camidge, D. Ross; Hodi, F. Stephen; McArthur, Grant A.; Miller, Wilson H., Jr.; Cervantes, Andres; Chow, Laura Q.; Lesokhin, Alexander M.; Rutten, Annemie; Sznol, Mario; Rishipathak, Deepali; Chen, Shang-Chiung; Stefanich, Eric; Pourmohamad, Tony; Anderson, Maria; Kim, Jeong; Huseni, Mahrukh; Rhee, Ina; Siu, Lillian L. Clinical Cancer Research, Vol.28 No.16, pp.3452-3463	DOI
2022-09	Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials Gettinger, Scott N.; Huber, Rudolf M.; Kim, Dong-Wan; Bazhenova, Lyudmila; Hansen, Karin Holmskov; Tiseo, Marcello; Langer, Corey J.; Paz-Ares Rodríguez, Luis G.; West, Howard L.; Reckamp, Karen L.; Weiss, Glen J.; Smit, Egbert F.; Hochmair, Maximilian J.; Kim, Sang-We; Ahn, Myung-Ju; Kim, Edward S.; Groen, Harry J.M.; Pye, Joanna; Liu, Yuyin; Zhang, Pingkuan; Vranceanu, Florin; Camidge, D. Ross JTO Clinical and Research Reports, Vol.3 No.9, p. 100385	DOI
2022-12	Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK plus Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study Ahn, Myung J.; Kim, Hye R.; Yang, James C. H.; Han, Ji-Yu; Li, Jacky Yu-Chung; Hochmair, Maximilian J.; Chang, Gee-Chen; Delmonte, Angelo; Lee, Ki H.; Campelo, Rosario G.; Gridelli, Cesare; Spira, Alexander, I; Califano, Raffaele; Griesinger, Frank; Ghosh, Sharmistha; Felip, Enriqueta; Kim, Dong-Wan; Liu, Yuyin; Zhang, Pingkuan; Popat, Sanjay; Camidge, D. Ross Clinical Lung Cancer, Vol.23 No.8, pp.720-730	DOI
2023-05	CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report Kim, Dong-Wan; Kim, Sang-We; Camidge, D. Ross; Shu, Catherine A.; Marrone, Kristen A.; Le, Xiuning; Blakely, Collin M.; Park, Keunchil; Chang, Gee-Chen; Patel, Sandip Pravin; Kar, Gozde; Cooper, Zachary A.; Samadani, Ramin; Pluta, Michael; Kumar, Rakesh; Ramalingam, Suresh Journal of Thoracic Oncology, Vol.18 No.5, pp.650-656	DOI